Preterm Labour (PTL) - Management of Threatened and Active PTL

Unique Identifier | NMP200/SSM/097 – v03.00
Document Type     | Clinical Guideline
Risk of non-compliance | may result in significant harm to the patient/DHB
Function          | Clinical Practice, Patient Care
User Group(s)     | Auckland DHB only
  • Organisation(s) | Women’s District Health Board
  • Directorate(s)  | Maternity
  • Department(s)   | Maternity
  • Used for which patients? | All antenatal patients that are referred to Auckland DHB
  • Used by which staff? | All clinicians in maternity service including Auckland DHB clinicians and Lead Maternity carers/NWH access holders
  • Excluded
Keywords           | Premature birth, fFN, fetal fibronectin, tocolysis, nifedipine, magnesium sulphate, corticosteroids, delayed cord clamping
Author             | MFM Consultant, Women’s Health
Authorisation      |
  • Owner           | Clinical Service Director - Secondary Maternity Services
  • Delegate / Issuer | Clinical Service Director - Secondary Maternity Services
Edited by          | Clinical Policy Advisor
First issued       | 01 February 2017
This version issued | 27 November 2018 - updated
Review frequency   | 3 yearly

Contents

1. Purpose of guideline .......................................................................................... 3
2. Management principles ....................................................................................... 3
3. Definition and risk factors ............................................................................... 3
4. Diagnosis of preterm labour ............................................................................. 4
  4.1 History taking ............................................................................................... 4
  4.2 Physical examination .................................................................................... 4
  4.3 Investigations .............................................................................................. 5
  4.4 Fetal Fibronectin (fFN) .............................................................................. 5
5. Point of Care Testing ......................................................................................... 7
6. PTL Care Plan Algorithm .................................................................................. 8
7. Management of confirmed active Preterm Labour 24⁺⁰⁻ 34⁺⁶ weeks ............... 9
  7.1 Admission to Labour and Birthing Unit ....................................................... 9
  7.2 Staff to be informed .................................................................................... 9
  7.3 Monitoring and assessment ......................................................................... 9
  7.4 Antenatal Corticosteroids .......................................................................... 9
  7.5 Magnesium Sulphate .................................................................................. 9
  7.6 Tocolysis ..................................................................................................... 10
  7.7 Neonatal Group B Streptococcal disease prevention .................................. 10

[Back to Contents]
7.8 In utero transfer ................................................................................................................ 10
7.9 Cord clamping................................................................................................................... 10
7.10 Future pregnancy risks after preterm birth ...................................................................... 10
8. Management of fFN > 200 ng/mL, not in active Preterm Labour ........................................ 11
  8.1 Admission to antenatal ward for observation ................................................................. 11
  8.2 Staff to be informed ........................................................................................................ 11
  8.3 Monitoring and assessment ............................................................................................ 11
  8.4 Antenatal Corticosteroids .............................................................................................. 11
  8.5 Magnesium Sulphate .................................................................................................... 11
  8.6 Tocolysis ........................................................................................................................ 11
  8.7 Neonatal Group B Streptococcal disease prevention ...................................................... 11
  8.8 In utero transfer ............................................................................................................. 12
  8.9 Cord clamping ............................................................................................................... 12
  8.10 On-going care ............................................................................................................... 12
9. Management of fFN 50 - 200 ng/mL, not in active preterm labour ........................................ 12
  9.1 Clinical review in WAU .................................................................................................. 12
  9.2 Antenatal Corticosteroids .............................................................................................. 12
  9.3 Discharge home with plan for review in WAU/DAU on the following day .................. 12
  9.4 Next day review in WAU/DAU ....................................................................................... 12
10. Management of fFN 0 - 49 ng/mL, preterm labour excluded ............................................. 13
11. Nifedipine tocolysis ......................................................................................................... 13
    Nifedipine tocolysis flowchart ......................................................................................... 15
12. Repeat presentation with symptoms of preterm labour .................................................... 16
13. Threatened and active PTL at < 24\textsuperscript{th} weeks ................................................... 16
14. Research ............................................................................................................................ 17
15. Future audit ....................................................................................................................... 17
16. Supporting evidence ........................................................................................................ 18
17. Associated documents ...................................................................................................... 19
18. Disclaimer ........................................................................................................................ 20
19. Corrections and amendments .......................................................................................... 20
1. Purpose of guideline

This guideline outlines the expected management of women presenting with threatened or active (established) preterm labour within Auckland District Health Board (Auckland DHB) or referred to Auckland DHB at gestations ≥ 24\(^{+0}\) weeks and < 37\(^{-0}\) weeks. Between 23\(^{+0}\) and 23\(^{+6}\) weeks gestation it may be appropriate to follow the pathway outlined in this guideline. However, this should only be done after reviewing Section 13 (Threatened and active PTL at < 24\(^{+0}\) weeks), and after discussion with both an obstetric specialist (and MFM when available) and neonatal specialist.

2. Management principles

Preterm birth is the leading cause of neonatal death and major morbidity. It imposes additional risks on infant, child and life-long health of the off-spring. The rate of preterm birth ranges from 5% to 18% of babies born worldwide and at National Women’s Health, Auckland City Hospital it is 9 - 10%. Approximately half of preterm births within the Auckland DHB unit are due to spontaneous labour or preterm pre-labour rupture of membranes (PPROM).

Current therapeutic strategies are unlikely to prevent preterm birth in women presenting with symptoms of preterm labour (PTL) (threatened PTL). However, we do have an opportunity to identify those at most risk of going onto preterm birth so interventions that reduce neonatal morbidity and mortality can be targeted appropriately.

Of women presenting with symptoms of PTL, 60 - 70% do not deliver until term and only 5% deliver within one week of presentation and therefore, clinical assessments of threatened PTL alone is a relatively poor predictor of preterm birth. The use of adjunct tests including vaginal biomarkers such as fetal fibronectin (fFN) or transvaginal ultrasound measurement of cervical length with strong negative predictive values allows us to rule out the risk of preterm birth in many women and limit the use of unnecessary antenatal admissions and interventions. Those interventions proven to be of value in improving neonatal outcomes include antenatal corticosteroids ≤ 34\(^{+6}\) weeks, magnesium sulphate < 30\(^{+0}\) weeks, delayed cord clamping and delivery within a unit with level 3 neonatal intensive care unit (NICU) facilities available. Tocolysis therapy has only been shown to have limited effects on outcome, however, it has been demonstrated to delay delivery > 48 hours therefore its use should be considered in women receiving a first course of antenatal corticosteroids at ≤ 34\(^{+6}\) weeks, magnesium sulphate at < 30\(^{+0}\) weeks or if antenatal transfer is required to access appropriate NICU facilities.

3. Definition and risk factors

**Preterm labour (PTL)**
- Refers to the onset of labour < 37\(^{-0}\) weeks gestation (and the fetus is deemed viable).
Clinically it is determined by regular uterine contractions with accompanied significant cervical dilatation of ≥ 3cm.

**Threatened PTL**
- Defined as uterine contractions but with no or limited evidence of cervical change at < 37+0 weeks gestation (and the fetus is deemed viable).
- Clinically it is difficult to differentiate those with threatened PTL who will go onto PTL and birth and those that will not.

**Risk factors for PTL**
Many cases of threatened PTL and PTL are not associated with any identifiable risk factors; however, there are certain conditions which may increase the risk:
- Previous PTL
- Preterm PPROM
- Previous second trimester loss
- History of cervical surgery (cone biopsy, LLETZ with depth ≥ 10 mm)
- History of ≥ 1 surgical termination of pregnancy or evacuation of retained products of conception after miscarriage
- History of caesarean section at full cervical dilatation
- Congenital uterine and/or cervical anomalies
- Multiple pregnancy
- Polyhydramnios
- Recurrent bleeding in first trimester (≥ 5 days)
- Placental abruption/antepartum haemorrhage
- Smoking, alcohol or illicit drug use

**4. Diagnosis of preterm labour**

**4.1 History taking**
- Review history for symptoms of labour or other diagnosis which may present with similar symptoms (eg APH, UTI, constipation) and review risk factors
- Confirm gestational age

**4.2 Physical examination**
- Examine for signs of PTL or other diagnosis which may present with similar symptoms
- Vital signs (temperature, pulse and BP)
- Abdominal palpation to detect uterine activity (frequency, duration and strength), assess fetal size and presentation
- Sterile speculum examination
- Avoid gel to allow fetal fibronectin (fFN) testing if indicated (see below)
- Look for pooling of liquor, discharge, cervical dilatation and length
• If pooling of liquor present, rupture of membrane is confirmed, refer to Rupture of Membranes in Pregnancy guideline (see associated documents)
• Digital vaginal examination
• Assess using Bishops score if cervix < 3cm dilated
• CTG - FHR pattern and evidence of uterine activity

4.3 Investigations
• MSU
• High vaginal swab for culture
• Consider use of fFN (see below) if ≤ 34+6 weeks
• If fFN is not available and ≤ 34+6 weeks, consider transvaginal ultrasound of cervical length.

<table>
<thead>
<tr>
<th>Cervical length</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 30mm</td>
<td>Treat as fFN 0 - 49 ng/mL</td>
</tr>
<tr>
<td>15 - 30mm</td>
<td>Assess clinical situation and discuss with specialist obstetrician on-call</td>
</tr>
<tr>
<td>≤ 15mm</td>
<td>Treat as fFN &gt; 200 ng/mL</td>
</tr>
</tbody>
</table>

4.4 Fetal Fibronectin (fFN)
Fetal Fibronectin is one of several commercially available vaginal biomarker tests for the prediction of preterm birth in women presenting with symptoms of PTL. To date fFN is the most extensively tested with data on predictive value in several thousand symptomatic women.

It is a glycoprotein found in amniotic fluid and extracts of placental tissue that can be thought of as ‘trophoblast glue’ promoting cellular adhesion at the utero-placental and decidual-fetal membrane interfaces. It is rarely detected at elevated levels in cervico-vaginal fluid in normal pregnancy during the second and third trimesters. However, it is released through mechanical or inflammatory mediated damage to the membranes or placenta before birth, and is therefore, found at elevated levels in the cervico-vaginal fluid of women between 22 and 36 weeks gestation who have an increased risk of PTL.

fFN should be used to identify women at most risk of PTL within the next seven days (when use of hospital admission, tocolysis and antenatal corticosteroids are being considered). Its greatest value lies in its negative predictive value.

The test uses an enzyme linked immunosorbent assay (ELISA) containing FDC-6 monoclonal antibody to detect fFN. Both a qualitative analyser (positive or negative result) and a quantitative analyser (absolute value 0 - 500 ng/mL) are commercially available. If using a qualitative analyser it has been established that the best threshold to define a positive/negative test result is 50 ng/mL. A negative result < 50 ng/mL has a strong negative predictive value for delivery within the next seven days (98 - 100%) i.e. women presenting with symptoms of PTL and a negative fFN are very unlikely (< 2%) to deliver within a time-frame where current hospital admission and corticosteroid use will be of benefit. Women with a positive test ≥ 50 ng/mL have a higher risk of delivery within the next seven days (positive predictive value 15 - 50%). However, the majority of women will still
not deliver within a time-frame where current hospital admission and other interventions may be of benefit.

Use of the quantitative analyser to obtain an absolute value of fFN is better able to identify those at highest risk and more appropriately tailor care to each individual woman ensuring antenatal care is not compromised to the detriment of mother and their babies who do go on to deliver preterm but reducing unnecessary interventions for all others. Using data including local Auckland DHB data obtained in the Biomarkers for Preterm Birth Study the following thresholds for care have been set:

<table>
<thead>
<tr>
<th>fFn result</th>
<th>Care plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>fFn 0 - 49 ng/mL</td>
<td>The women should be discharged home with no acute intervention if no other diagnosis is considered to be the cause of their symptoms.</td>
</tr>
<tr>
<td>fFn 50 - 200 ng/mL</td>
<td>The women should be considered for corticosteroids if ≤ 34+6 weeks and these should be administered in WAU with women then discharged home (if no other diagnosis is considered to be the cause of their symptoms). Women should be reviewed in WAU/DAU the following day for administration of second dose of corticosteroid. Women should be clearly informed of signs and symptoms that should precipitate an early return to hospital. Review in an obstetric clinic one week later should be arranged. The women should be advised that they are at an increased risk of early birth but are still more likely to continue their pregnancy to term.</td>
</tr>
<tr>
<td>fFn &gt; 200 ng/mL</td>
<td>The women should be admitted to hospital and considered for tocolysis therapy and corticosteroids if ≤ 34+6 weeks. Discussion with neonatology service should occur to ensure an appropriate neonatal cot is available in event of birth (and consider in-utero transfer if not available). The women should be advised that they are at an increased risk of early birth but may still continue their pregnancy to term.</td>
</tr>
</tbody>
</table>

Indications for fFN testing:

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria*</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Fetus is alive and viable</td>
<td>▪ Other complications have been identified that warrant delivery within the next seven days (and admission/use of corticosteroids) eg abruption</td>
</tr>
<tr>
<td>▪ 24+0 - 34+6 weeks gestation</td>
<td>▪ PPROM</td>
</tr>
<tr>
<td>▪ 23+0 - 23+6 weeks gestation if active intervention is being considered**</td>
<td>▪ Higher order multiple pregnancy (≥ triplets)</td>
</tr>
<tr>
<td>▪ Membranes are intact</td>
<td></td>
</tr>
<tr>
<td>▪ Cervix is &lt; 3cm dilated</td>
<td></td>
</tr>
<tr>
<td>▪ Corticosteroid use, +/- tocolysis, +/- magnesium sulphate are being considered</td>
<td></td>
</tr>
<tr>
<td>▪ Singleton and twin pregnancy</td>
<td></td>
</tr>
</tbody>
</table>
**Relative contraindications** to use of fFN include; current vaginal bleeding, sexual intercourse within last 24 hours, speculum or digital vaginal examination within the last 24 hours, transvaginal ultrasound examination within the last 24 hours. These factors will increase the likelihood of a positive fFN result (but may represent a false positive). However, a negative result will be a true negative result and women can be managed according to that result. The use of a fFN test can still be considered if the result may influence management provided eg the clinician would be confident to discharge the woman and withhold corticosteroids and tocolyis if the result is negative. It is recommended that these cases are discussed with the specialist obstetrician on-call.

**fFN can be taken at time of first examination at 23\textsuperscript{0} - 23\textsuperscript{6} weeks and only sent after consideration of case and full discussion with specialist obstetrician on-call, neonatologist and parents (refer to Section 13 - Threatened and active PTL at < 24\textsuperscript{0} weeks).**

The use of a gel lubricant at the time of testing may produce a false negative result. This should be avoided.

**Specimen collection:**

This should be done at the time of first speculum examination. The speculum examination should use water as a lubricant (no gel). Collection of the fFN specimen should be prior to any other cervical examination or swab. Place fFN swab into posterior fornix of vagina and rotate for 10 seconds. Place the swab into the fFN plastic specimen collection tube.

Proceed with remainder of vaginal assessment and follow the PTL Care Plan Algorithm for ongoing care. If assessment is not suggestive of significant risk of PTL, the fFN sample can be stored before processing for up to six hours at room temperature and three days in the refrigerator if required.

**Note:** there is no cost involved in taking the swab, cost to Auckland DHB is only incurred when sample is processed.

5. **Point of Care Testing**

The Auckland DHB Point of Care Testing service provides an overview of testing using the Hologic fFN instrument. The following documents are provided to assist the user in obtaining a fFN result which can be used to aid clinical patient management:

1. fFN overview
2. Specimen collection
3. Important points (both around collection and use of the instrumentation)
4. Sample analysis
6. PTL Care Plan Algorithm

Presentation with **signs and symptoms of preterm labour at 24° - 34° weeks gestation** where admission, corticosteroids, tocolysis, +/- magnesium sulphate would normally be considered

Evidence of PPROM (refer to **Rupture of Membranes in Pregnancy** guideline)

- Sterile speculum examination (with no lubricant)
  - Assess for PPROM
  - Visualise cervix
  - fFN from posterior fornix
  - High vaginal swab

No evidence PPROM

- Perform digital vaginal examination

**If ≥ 3cm dilated**

**ACTIVE PRETERM LABOUR**

- Admit to Labour & Birthing Unit
- Inform appropriate staff
- Instigate monitoring and assessment
- Administer corticosteroids
- Administer magnesium sulphate at <30° weeks
- Administer tocolysis
- Administer GBS prophylaxis
- Consult with neonatal services and consider **in utero** transfer if no suitable neonatal cot available
- Plan delayed cord clamping (60 seconds) at birth

FFN > 200 ng/mL, NOT IN ACTIVE PRETERM LABOUR

- Admit to antenatal ward
- Consult with neonatal services and consider **in utero** transfer if no suitable cot available
- Instigate monitoring and assessment
- Administer corticosteroids
- Do not give magnesium sulphate
- Administer tocolysis if regular painful contractions
- Do not give GBS prophylaxis
- Discharge home at 48 hours if well with advice regarding signs and symptoms and to return if recur
- Obstetric clinic review in one week

FFN 50 - 200 ng/mL, NOT IN ACTIVE PRETERM

- Clinical review to exclude other causes of symptoms
- Administer corticosteroids
- Discharge home with advice regarding signs and symptoms to return if recur
- WAU/DAU following day for second dose corticosteroids
- Obstetric clinic review in one week

FFN 0 - 49 ng/mL, PRETERM LABOUR EXCLUDED

- Clinical review to exclude other causes of symptoms
- Provide reassurance to woman and family
- Discharge home with advice regarding signs and symptoms to return if recur
- LMC follow-up in one week

If contractions increase, repeat digital vaginal examination: If ≥ 3cm dilated

**ACTIVE PRETERM LABOUR**
7. Management of confirmed active Preterm Labour 24Ω- 34Ω weeks

7.1 Admission to Labour and Birthing Unit

7.2 Staff to be informed

- Labour and Birthing Unit clinical charge midwife
- Specialist obstetrician on-call
- Neonatal staff
  - Level 3 team if < 32Ω weeks
  - Level 2 team if ≥ 32Ω weeks

7.3 Monitoring and assessment

- Insert IV line
- Obtain full blood count, CRP and group and hold sample
- Confirm fetal presentation by ultrasound scan
- Maternal monitoring (see Intrapartum Care - Normal Labour and Birth guideline in associated documents)
- Fetal monitoring (see Fetal Surveillance policy in associated documents). Continuous CTG should be performed while in active labour
- At peri-viable gestations 23Ω- 25Ω weeks - individual plan to be made in consultation with parents and specialist obstetrician on-call (+/-MFM specialist) and neonatal team regarding degree of monitoring and level of intervention (eg whether intrapartum CS should be performed for fetal distress). At < 24Ω refer to Threatened and active PTL at < 24Ω weeks for further guidance (section 13)

7.4 Antenatal Corticosteroids

- Refer to Antenatal Corticosteroids to Improve Neonatal Outcomes guideline in associated documents.
  - Should be considered for all women ≤ 34Ω weeks gestation
  - In women who have received previous corticosteroids in this pregnancy, refer to guideline for repeat doses.

7.5 Magnesium Sulphate

- Should be considered for all women < 30Ω weeks gestation
- Refer to Magnesium Sulphate for Pre-eclampsia and for Neuroprotection in Pre-term Births < 30Ω Weeks guideline in associated documents
- Magnesium sulphate therapy should not be offered at 30Ω - 33Ω weeks gestation until the results of the MAGENTA trial are available and considered (recruitment completed February 2018)
7.6 **Tocolysis**
- Should be considered for all women ≤ 34+6 weeks gestation to allow time for corticosteroid, +/- magnesium sulphate administration (and rarely in utero transfer)
- Nifedipine (section 11) should be the first-line tocolytic agent. It is administered orally with less side effects than other available tocolytic agents (betamimetics)
- Refer to and follow the Nifedipine use flowchart

7.7 **Neonatal Group B Streptococcal disease prevention**
- Preterm birth is a risk factor for neonatal group B streptococcal disease
- Group B streptococcus prophylaxis should be offered for all women in active PTL Refer to Group B Streptococcus (GBS) - prevention of early - Onset Neonatal Infection guideline in associated documents
- Treatment should continue until birth or until the patient is transferred from Labour and Birthing Unit if symptoms of PTL settle and the patient remains undelivered

7.8 **In utero transfer**
- The case should be discussed with the neonatal team to ensure that the required level of care is currently available at Auckland City Hospital (ACH) Neonatal Intensive Care Unit (NICU)
- Consider antenatal transfer if it is necessary and if it is deemed safe

7.9 **Cord clamping**
- Delayed cord clamping (60 seconds) at the time of preterm birth has a beneficial effect on neonatal outcome reducing mortality for all births < 37 weeks (RR 0.68, 95% CI 0.52 - 0.90) and ≤ 28 weeks (RR 0.70, 95% CI 0.51-0.95) with no reported adverse effects for mother or neonate and so should be used for all births regardless of mode of delivery, plurality or indication for preterm birth
- At the time of birth, the neonate should be held below the level of introitus or placenta with no palpation or milking of the cord. A clock or stopwatch should be used to time 60 seconds before clamping the cord in the usual way and handing the baby to the neonatal team
- Oxytocic drugs should be used in the usual manner and can be given before or after cord clamping. Delayed cord clamping is not associated with an increased risk of postpartum haemorrhage

7.10 **Future pregnancy risks after preterm birth**
- Medical review should occur prior to hospital discharge and advice regarding the risk of recurrence should be given
- If delivery < 34+0 weeks gestation, recommendation should be given for early specialist review during the next pregnancy
- Consider referral to the Preterm Birth Clinic for pre-pregnancy consult or in future pregnancy
8. Management of fFN > 200 ng/mL, not in active Preterm Labour

8.1 Admission to antenatal ward for observation

8.2 Staff to be informed
   • Neonatal staff
     - Level 3 team if < 32⁺⁰ weeks
     - Level 2 team if ≥ 32⁺⁰ weeks

8.3 Monitoring and assessment
   • Insert IV line
   • Obtain full blood count, CRP and group and hold sample
   • Confirm fetal presentation and assessment of estimated fetal weight by ultrasound scan
   • Maternal monitoring: four hourly pulse, BP and temperature (more frequent in first three hours of nifedipine use, refer to the Nifedipine use flowchart)
   • Fetal monitoring: daily CTG unless uterine activity (refer to the Nifedipine use flowchart)

8.4 Antenatal Corticosteroids
   • Refer to Antenatal Corticosteroids To Improve Neonatal Outcomes guideline in associated documents
     - Should be considered for all women ≤ 34⁺⁶ weeks gestation
     - In women who have received previous corticosteroids in this pregnancy, refer to guideline for repeat doses

8.5 Magnesium Sulphate
   • Should not be routinely used. Consider in women < 30⁺⁰ weeks gestation only if they progress to active PTL
   • Refer to Magnesium Sulphate for Pre-eclampsia and for Neuroprotection in Pre-term Births < 30⁺⁰ Weeks guideline in associated documents

8.6 Tocolysis
   • Should be considered for all women ≤ 34⁺⁶ weeks gestation with on-going painful uterine contractions to allow time for corticosteroid administration
   • Nifedipine (section 11) should be the first-line tocolytic agent. It is administered orally with less side effects than other available tocolytic agents (betamimetics)
   • Refer to and follow the Nifedipine use algorithm

8.7 Neonatal Group B Streptococcal disease prevention
   • Should not be routinely used. Consider in women < 37⁺⁰ weeks gestation if they progress to active PTL
   • Refer to Group B Streptococcus (GBS) - prevention of early - Onset Neonatal Infection guideline in associated documents
8.8 In utero transfer
- The case should be discussed with the neonatal team to ensure that the required level of care is currently available at ACH NICU
- Consider antenatal transfer if it is necessary and if it is deemed safe

8.9 Cord clamping
- Document a plan for delayed cord clamping (60 seconds) in event of woman going onto preterm birth <37 weeks

8.10 On-going care
- The majority of women admitted with symptoms of PTL and fFN > 200 ng/mL will not deliver within the next seven days. If they are well and symptom free they should be discharged home at 48 hours
- A referral should be made for a specialist clinic review in one week
- All women should be advised of signs and symptoms of preterm labour with a plan for return if symptoms recur

9. Management of fFN 50-200 ng/mL, not in active preterm labour

Patients with symptoms of PTL and a fFN 50-200 ng/mL are unlikely to deliver within the next few days but may be at risk of preterm birth (at a later time) and hence admission to hospital at current time is unlikely to make a significant impact on improving outcomes.

9.1 Clinical review in WAU
- Exclude other causes of symptoms eg UTI, placental abruption

9.2 Antenatal Corticosteroids
- Refer to Antenatal Corticosteroids To Improve Neonatal Outcomes guideline in associated documents
  - Should be considered for all women ≤ 34+6 weeks gestation
  - In women who have received previous corticosteroids in this pregnancy, refer to guideline for repeat doses

9.3 Discharge home with plan for review in WAU/DAU on the following day
- Advice should be given regarding signs and symptoms of preterm labour and plan for earlier return if symptoms recur

9.4 Next day review in WAU/DAU
- Review any current symptoms
- Administer the second dose of corticosteroid
- Follow-up in obstetric clinic in one week
10. Management of fFN 0 - 49 ng/mL, preterm labour excluded

Patients with symptoms of PTL and fFN 0 - 49 ng/ml are very unlikely to deliver within the next seven days (< 2%)

- Reassurance should be given to these patients
- Clinical review to exclude other causes of symptoms eg UTI, placental abruption
- Discharge home with advice regarding signs and symptoms of preterm labour and plan for return if symptoms recur
- Follow-up with LMC in one week

11. Nifedipine tocolysis

Tocolysis therapy has only been shown to have limited effects on outcome in relatively small studies and is not a standard of care in some countries, regions and hospitals. However, it has been demonstrated to delay delivery > 48 hours and so its use should be considered in women receiving a first course of antenatal corticosteroids at ≤ 34\(^{+6}\) weeks, magnesium sulphate at < 30\(^{+0}\) weeks or if antenatal transfer is required to access appropriate NICU facilities.

There are a number of tocolytic agents. Of those available in New Zealand and where there is evidence to support use, nifedipine is first-line therapy. Manufacturers may not recommend nifedipine use in pregnancy, however, there are a number of studies of its use as a tocolytic agent and it is accepted as a standard treatment for hypertension in pregnancy. It is administered orally with less side effects than other available tocolytic agents (betamimetics). Two preparations of nifedipine are used within the tocolysis flowchart - short acting nifedipine and slow release nifedipine.

**Trade name:** Adalat® 5 mg capsules (short acting nifedipine) (section 29), Nyefax Retard® 20 mg tablets (slow release nifedipine)

**Mechanism of action:** Calcium channel blocker

**Contraindications:**

- **Absolute:**
  - Suspected/confirmed intrauterine infection
  - Suspected/confirmed placental abruption
  - Significant hypotension
  - Maternal shock
  - Previous allergic response to nifedipine

- **Relative:**
  - Use of β-blocker (risk of hypotension)
  - Lethal congenital anomalies of the fetus
  - Severe fetal growth restriction with suspected fetal compromise
  - Abnormal CTG
Possible adverse effects:
- Most common: transient palpitation, headaches and facial flushing
- Less common: constipation, dizziness, nausea, tachycardia, fatigue, peripheral oedema, increased liver enzymes. Liver enzyme changes are not a concern with such a limited use, but care should be taken in those with known liver disease

Dose and administration:
- Refer to Nifedipine use algorithm
- Initial dosing: Short acting nifedipine 10 mg (2 x 5 mg capsules) (Adalat®) every 15 minutes if still contracting (up to 4 doses)
- Maintenance: Slow release nifedipine 8 hourly 20 - 40 mg (maximum of 160 mg in 24 hours) (Nyefax Retard)
- Dose can be adjusted according to clinical symptoms
- Slow release nifedipine should be discontinued 12 hours after the last corticosteroid dose. There is no data to support continued maintenance therapy

Monitoring:
Maternal:
- First hour: pulse, BP at 0, 30 and 60 minutes
- Next 2 hours: pulse, BP and temperature hourly
- Remaining time on treatment: pulse and BP four hourly

Fetal:
- Baseline CTG must be normal before commencement of therapy
- CTG at commencement of treatment
- Continuous CTG for the first hour and until painful contractions cease
- Subsequent CTG daily or as clinically indicated eg increase in maternal temperature or pulse rate or return/increase in contractions
Nifedipine tocolysis flowchart

ACTIVE PRETERM LABOUR
or
FFN > 200 ng/mL, NOT IN ACTIVE PRETERM LABOUR (& regular painful contractions)
at 240-346 weeks gestation and corticosteroids and/or magnesium sulphate not yet completed or if antenatal transfer is planned

No contraindication to tocolysis

Time 0
- Short acting nifedipine 2 x 5 mg po (Adalat®)
- Pulse and BP
- Continuous CTG

Time 15 mins
- Short acting nifedipine 2 x 5 mg po (Adalat®) if still contracting
- Continuous CTG

Time 30 mins
- Short acting nifedipine 2 x 5 mg po (Adalat®) if still contracting
- Pulse, BP and temperature
- Continuous CTG

Time 45 mins
- Short acting nifedipine 2 x 5 mg po (Adalat®) if still contracting
- Continuous CTG

Time 60 mins
- Slow release nifedipine (Nyefax Retard®) 20 - 40 mg po and chart every 8 hours
- Pulse, BP and temperature hourly for 2 hours and then four hourly
- Stop CTG if contractions settled and repeat

Time 36 hours
(12 hours after second corticosteroid dose)
- Last dose slow release nifedipine (Nyefax)
12. Repeat presentation with symptoms of preterm labour

Women who present with symptoms of PTL but who do not go onto to deliver will be discharged from hospital with advice to return if symptoms recur (fFN 0 - 200 ng/mL on day of review and fFN > 200 ng/mL 48 hours after admission). If they represent with recurrence of symptoms of PTL ≤ 34+6 weeks they should undergo the same clinical review as those presenting for the first time (refer to Diagnosis of Preterm Labour - section 4).

For women in active preterm labour, follow management of confirmed active Preterm Labour algorithm (section 7).

For women with fFN > 200 ng/mL but cervical dilatation < 3 cm, follow management of fFN > 200 ng/mL, but not in active Preterm Labour algorithm (section 8).

For women with fFN 50 - 200 ng/mL, follow management of fFN > 200 ng/mL, but not in active Preterm Labour algorithm (section 9)

For women with fFN 0 - 49 ng/mL, follow management of fFN 0-49 ng/mL, Preterm Labour excluded algorithm (section 10).

13. Threatened and active PTL at < 24+0 weeks

Over the last 10 - 20 years there have been significant improvements in survival and survival free of major morbidity in infants born at peri-viable gestational ages (23+0 - 25+0 weeks). Active interventions including the use of antenatal corticosteroids and magnesium sulphate are likely to be significant influencing factors on survival and survival free from major morbidity. It is therefore appropriate to consider a more pro-active approach to care when women present with symptoms of PTL at 23+0 - 23+6 weeks.

‘Active intervention’ < 24+0 weeks should not form standard routine care but each case must be individualised and tailored ensuring a multidisciplinary and family-centred approach to the care that is offered. All cases must be discussed with the specialist obstetrician on-call +/- MFM subspecialist and a review of factors likely to influence outcome should be made. These factors include; presence of SGA and markers of fetal well-being (umbilical and other fetal Doppler waveforms, amniotic fluid volume); evidence of PPROM +/- chorioamnionitis; abnormal fetal heart rate recording; presence of suspected fetal anomaly/malformation; fetal sex (where known); multiple gestation; and whether antenatal corticosteroids and magnesium sulphate have been administered (or sufficient time may be gained to administer them).

After careful consideration of these factors and discussion in advance with the on-call neonatology team, ‘active intervention’ should be offered to parents as an option but support also given for a more conservative approach to care. Ideally counselling should be provided by the specialist obstetrician on-call and specialist neonatologist on-call. If ‘active intervention’ is planned, the PTL Care Plan Algorithm (section 6) including the use of a fFN swab, where appropriate, should be followed.
If ‘active intervention’ is planned, the neonatology team should attend delivery. Assessment may include on-going appraisal of any intra-partum factors that have developed, birth weight, baby’s condition at birth and response to resuscitation in addition to factors known in advance. A plan for ‘active intervention’ at the time of presentation does not commit caregivers to full resuscitation after birth if this is not deemed to be in the baby’s best interest, and antenatal counselling should cover this eventuality.

Discussion regarding use of caesarean section (CS) at gestational age 23\(^{10} - 23^{6}\) weeks should be included in parental counselling. A plan for ‘active intervention’ at the time of presentation does not commit parents or caregivers to perform a CS but this should be considered and discussed and there should be a plan documented. It is likely that a classical CS (or high transverse incision) may be required and the implications for a future pregnancy considered (i.e. need for elective CS). It is not clear that CS in some cases (eg for breech presentation or for CTG evidence of fetal distress) will improve outcome for the fetus/neonate, however, in others (eg transverse lie) where a decision for ‘active intervention’ has been made, it is likely to be beneficial. If a decision has been made not to perform CS for fetal indications, continuous CTG monitoring in labour is not recommended. However, intermittent fetal heart rate auscultation may aid the neonatal team’s care at time of delivery and should be performed and documented.

fFN testing can be used at gestational ages > 22\(^{10} \) weeks but should only be considered if it is likely to significantly influence management decisions.

14. Research

The optimal management and care of women presenting with symptoms of preterm labour is constantly evolving. Over the last 30 - 40 years clinical trial research has led to significant improvements in neonatal survival and survival free from major morbidity due to preterm birth. However, it is still a leading cause of perinatal death and has a huge cost both financially and emotionally to the families we care for and for our society as a whole. National Women’s Health has a strong history of contribution to trials around preterm birth, for example, APTS (Australian Placenta l Transfusion Study), ASTEROID (Dexamethasone vs Betamethasone prior to Preterm Birth, MAGENTA (use of magnesium sulphate prior to delivery 30 - 34 weeks) and PPROMT (management of PPROM at 34 - 37 weeks). National Women’s Health are committed to ongoing research to further improve the care provided and all women presenting with symptoms of PTL who are eligible for on-going clinical trials that may be of benefit must be offered and actively encouraged to participate.

15. Future audit

There are a number of auditable standards within this guideline. These should be reviewed regularly and practice should be audited. Examples include:

- Use of fFN in women presenting with symptoms of PTL
• Invitation to join relevant research studies
• Adherence to use of management strategies according to PTL Care Plan algorithm
  o admission rates
  o use of tocolysis
  o use of corticosteroids, use of magnesium sulphate
  o discharge with next day WAU/DAU review in in women with fFN 50 - 200 ng/mL not in active PTL
  o discharge at 48 hours in women with fFN > 200 ng/mL not in active PTL

16. Supporting evidence


17. Associated documents

• [Antenatal corticosteroids to improve neonatal outcomes](https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp128_mag_sulphate_child.pdf)
• [Diabetes in Pregnancy](https://www.who.int/mediacentre/factsheets/fs363/en/)
• [Fetal Surveillance Policy](https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp128_mag_sulphate_child.pdf)
18. Disclaimer

No guideline can cover all variations required for specific circumstances. It is the responsibility of the health care practitioners using this Auckland DHB guideline to adapt it for safe use within their own institution, recognise the need for specialist help, and call for it without delay, when an individual patient falls outside of the boundaries of this guideline.

19. Corrections and amendments

The next scheduled review of this document is as per the document classification table (page 1). However, if the reader notices any errors or believes that the document should be reviewed before the scheduled date, they should contact the owner or Document Control without delay.